The combination contains a notoriously porphyrinogenic sulfonamide component, inducer of CYP3A4. Several references warn against it. Trimetoprim is substrate for CYP2C9 and 3A4. Inhibits CYP2C8, 2C19, 2D6, 3A4. Warned against in three references.
Chemical description
Sulfamethoxazol: Sulfonamide excreted in urine in unchanged form (20%), in acetylated form (60%) and in glucuronidated form (15%). Trimethoprim: Bacteriostatic antibiotic perorally used (150-200mg x 2) in urinary tract infections. About 10-20% is metabolized in the liver. About 50% is excreted by the kidneys in unchanged form within 24 hours.
Personal communication
Andersson: Precipitates attacks (n=4).
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes
J01E /
J01EE or
go back.